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2 
Abstract 24 
Polymer-drug conjugates have been actively developed as potential anticancer drug delivery 25 
systems. In this study, we report the first polymer-anticancer drug conjugate with poly(glycerol 26 
adipate) (PGA) through the successful conjugation of methotrexate (MTX). MTX-PGA 27 
conjugates were controllably and simply fabricated by carbodiimide-mediated coupling reaction 28 
with various high molar ratios of MTX. The MTX-PGA conjugate self-assembled into 29 
nanoparticles with size dependent on the amount of conjugated MTX and the pH of medium. 30 
Change in particle size was attributed to steric hindrance and bulkiness inside the nanoparticle 31 
core and dissociation of free functional groups of the drug. The MTX-PGA nanoparticles were 32 
physically stable in media with pH range of 5-9 and ionic strength of up to 0.15 M NaCl and 33 
further chemically stable against hydrolysis in pH 7.4 medium over 30 days but enzymatically 34 
degradable to release unchanged free drug. Although 30%MTX-PGA nanoparticles exhibited 35 
only slightly less potency than free MTX in 791T cells in contrast to previously reported human 36 
serum albumin-MTX conjugates which had >300 times lower potency than free MTX. However, 37 
the MTX nanoparticles showed 10 times higher toxicity to Saos-2 cells than MTX. Together 38 
with the enzymic degradation experiments, these results suggest that with a suitable 39 
biodegradable polymer a linker moiety is not a necessary component. These easily synthesised 40 
PGA drug conjugates lacking a linker moiety could therefore be an effective new pathway for 41 
development of polymer drug conjugates.  42 
Keywords: Poly(glycerol adipate); Methotrexate; Polymer-drug conjugate; Nanoparticle; 43 
Osteosarcoma cell 44 
Abbreviations 45 
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HSA-MTX, Human serum albumin-methotrexate conjugates; MTX, Methotrexate; MTX-PGA, 46 
Methotrexate-conjugated poly(glycerol adipate); PCE, Porcine carboxylesterase enzyme; PDC, 47 
Polymer-drug conjugates; PGA, Poly(glycerol adipate) 48 
1. Introduction 49 
Polymer-drug conjugates are once more being actively pursued as potential anticancer agents, 50 
and a range of different drugs and polymers are under investigation [1]. Drugs are required to be 51 
both potent in molar terms and have a chemical functional group for effective delivery which 52 
gives a limited choice, and among the favourites from earlier studies was methotrexate (MTX). 53 
There is also a close connection between polymer drug delivery and targeted drug delivery in 54 
which drugs are linked to antibodies, and MTX was the first drug to be used for this type of work 55 
[2].  The fields of polymer-drug conjugates and antibody targeted MTX are also connected 56 
through work by Garnett and co-workers who constructed human serum albumin-MTX (HSA-57 
MTX) conjugates linked to monoclonal antibodies which were particularly potent and selective 58 
[3, 4]. This early work on antibody-MTX conjugates has been comprehensively reviewed [5]. 59 
MTX still has some advantages in polymer-drug conjugates, as unlike the anthracyclines it is 60 
quite robust chemically, but has similar potency in sensitive cancers.  61 
Many efforts have been made to develop macromolecular based drug delivery systems for MTX 62 
including polymer-drug conjugates, microparticles and nanoparticles [6, 7]. Several polymers 63 
have been proposed to deliver MTX using a polymer-drug conjugate approach such as human 64 
serum albumin [8], poloxamer [9], hydroxyethyl starch [10], polypeptide [11], poly(L-lysine) 65 
[12], chitosan [13, 14]. Polymer-MTX conjugates can circumvent drug resistance, increase 66 
MTX’s half-life and potentiate its antitumour efficacy better than the MTX-physically-entrapped 67 
particulate carriers [12, 15]. One of the principal causes of MTX resistance is due to 68 
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downregulation of uptake pathways, and it has been shown that resistance can be largely 69 
overcome by macromolecular conjugates delivered by the lysosomotropic route [16]. A key 70 
feature of polymer-drug conjugates is that a biodegradable linkage is required to release drug at 71 
the target site through a lysosomotropic mode of action [17, 18]. For many of the earlier 72 
conjugates with HSA and poly-L-lysine, it appears to be assumed that these amide-linked natural 73 
and semisynthetic polymers would release drug due to the proteolytic degradation in the 74 
lysosomal compartment. However, later work by Fitzpatrick and Garnett showed that this 75 
degradation was limited and inefficient, and led largely to the release of lysyl-MTX derivatives 76 
[19, 20].  77 
In addition to the limited number of drugs which can be conjugated, there are also a limited 78 
number of suitable functional polymers for producing polymer-drug conjugates.  Key work on 79 
understanding polymer-drug conjugates employed hydroxypropyl methacrylamide, a plasma 80 
expander [21].  However, as this was a non-biodegradable polymer, suitable linkages to release 81 
the drug had to be incorporated and many such linkages have been described [1, 22], but these 82 
are mainly designed for drugs like doxorubicin attached by a free amine on the drug. A suitable 83 
linkage has also been developed for MTX release [19, 20], however, non-biodegradable 84 
polymers have a further disadvantage in that they can be difficult to eliminate from the body. For 85 
the production of the simplest and most effective polymer-drug conjugates, a biodegradable 86 
functional polymer would be the best way forward, eliminating the need for inclusion of a 87 
degradable linker.  88 
Poly(glycerol adipate) (PGA) has been introduced in the pharmaceutical and drug delivery fields 89 
due to its versatility and well-suited characteristics for potential clinical use. It consists of two 90 
non-toxic monomers, namely glycerol and adipic acid, linked with ester bonds [23]. Major 91 
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advantages of PGA are biocompatibility with the body and biodegradability by human enzymes 92 
producing non-toxic removable metabolites [24]. Further major advantages over other 93 
biodegradable amphiphilic polymers is that every repeating unit of PGA contains a pendant 94 
hydroxyl group along the polymer backbone offering the potential for high drug loading using an 95 
easy synthetic route. The conjugation of MTX at available hydroxyl groups of PGA leads to a 96 
hydrolysable ester linkage of the conjugates which may release the active parent free drug after 97 
internalisation in cancer cells. Previously used polymers have significant disadvantages. 98 
Albumin and poly-L-lysine do not result in significant release of free drug [8, 12]. Poloxamer, 99 
hydroxyethyl starch and chitosan are not significantly biodegradable and polymers such as 100 
poloxamer have only terminal groups available for conjugation of drug [9, 10, 13, 14]. These 101 
properties variously result in low drug loading and lower cytotoxicity compared to the parent 102 
drug. Furthermore, recent work on MTX-conjugated biodegradable poly(ε-caprolactone)-co-103 
poly(ethylene glycol) required several steps of synthesis and inclusion of a triazole linker 104 
between drug and polymer [25, 26]. Therefore, the above characteristics of PGA are 105 
advantageous and potential for anticancer drug delivery. Up to now, there have been no reports 106 
on polymer-anticancer drug conjugates using PGA as a backbone.  107 
The aim of the present work is to synthesise MTX-PGA polymer-drug conjugates and to 108 
determine their properties. Due to the amphiphilicity of the polymer [27], the polymer-drug 109 
conjugates are expected to be assembled into small nanoparticles in a similar fashion to that 110 
reported by the Kataoka group on PEG-polyaspartate-adriamycin conjugate micelles [28]. Also 111 
we aim to assess their efficacy for this work in comparison to historical efficacy data on HSA-112 
MTX conjugates to help elucidate mechanistic advantages which may lead to development of 113 
more effective polymer-drug conjugates for cancer therapy. 114 
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2. Materials and methods 115 
2.1. Materials 116 
PGA was synthesized according to the previously published method [29]. MTX and porcine 117 
carboxylesterase (PCE, with activity of 18 units/mg solid) were used as received from Sigma-118 
Aldrich, Missouri, USA. N,N'-Dicyclohexylcarbodiimide (DCC), 4-(dimethylamino)pyridine 119 
(DMAP) were bought from Fluka, Tokyo, Japan.  Osteosarcoma cell line 791T originally 120 
obtained from the U.S. Naval Biomedical Center, Oakland, USA [30], was obtained from Prof L 121 
Durrant, Department of Medicine, Nottingham City Hospital, University of Nottingham, a 122 
culture of the cell line used in the works originally published by Garnett et al [3, 4, 19, 20]. Saos-123 
2 cell line (human primary osteogenic sarcoma, ATCC number HTB-85) was kindly gifted from 124 
Dr. Pakpoom Kheolamai, Division of Cell Biology, Faculty of Medicine, Thammasat University, 125 
Thailand. Eagles Minimum Essential Medium (MEM) and glutamine solution were obtained 126 
from Sigma-Aldrich (Dorset, UK). Dulbecco’s modified Eagle’s medium (DMEM) powder, low 127 
glucose, Dulbecco’s phosphate buffered saline (DPBS) without calcium chloride without 128 
magnesium chloride and PrestoBlue® cell viability reagent were purchased from Life 129 
Technologies Corporation, Oregon, USA. Sodium pyruvate was obtained from Merck KGaA, 130 
Damstadt, Germany. 0.05% Trypsin-EDTA was collected from Gibco® (Invitrogen Ltd, Paisley, 131 
UK). Resazurin was sourced from Acros Organics (Loughborough, UK). Foetal bovine serum 132 
(FBS) was supplied by Invitrogen Ltd (Paisley, UK). Commercially available sterile 133 
methotrexate solution for injection (25 mg/mL) was obtained from Mylan, Hatfield, UK. 134 
Dimethyl formamide (DMF) and acetonitrile were of high performance liquid chromatography 135 
(HPLC) grade and used as received. Dimethyl sulfoxide (DMSO) was dried using molecular 136 
sieves prior to use. Water employed throughout this study was deionized (DI) grade or higher.  137 
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2.2. Synthesis of MTX-conjugated PGA (MTX-PGA) polymers 138 
Conjugates of varying nominal MTX % mole with respect to PGA polymer repeating unit were 139 
produced by a simple carbodiimide coupling reaction. In brief, PGA (1 g = 4.95 mmole glycerol 140 
adipate repeating units) was dissolved in dried DMSO (10 mL). Calculated amounts of MTX 141 
(1.5 equiv.), DCC (1.2 equiv.) and DMAP (0.3 equiv.) relative to the mol% nominal value of 142 
polymer repeating units were then added. The reaction was stirred for 72 h and protected from 143 
light. After that, the precipitate was removed by centrifugation at 4500 rpm, 4°C for 15 min. The 144 
supernatant was collected and precipitated in methanol. The precipitate was washed with 145 
methanol for another 3 times and re-dissolved in a small volume of DMSO. The polymer 146 
solution was dialyzed against DI water for 24 h using dialysis bag (MWCO 12,400 Da, Sigma-147 
Aldrich, Missouri, USA). Finally, the polymer was freeze dried for 24 h. The dried polymer was 148 
kept in a desiccator until use.  149 
2.3. Polymer characterization 150 
2.3.1. IR spectroscopy 151 
Presence of drug in conjugated PGA polymer was first assessed by infrared (IR) spectroscopy 152 
using an Attenuated Total Reflection (ATR) spectrometer (Agilent Cary 630 FTIR, Agilent 153 
Technologies, Santa Clara, USA). The spectra were recorded with a resolution of 4 cm-1 over the 154 
range of 4000-650 cm-1 by recording 32 interferograms. 155 
2.3.2. Nuclear magnetic resonance (NMR) spectroscopy 156 
The quantitation of drug coupling and structure of MTX-PGA polymers were investigated by 157 
proton 1H NMR spectroscopy. The spectra were recorded by Bruker 400 MHz spectrometer 158 
(Bruker corporation, Rheinstetten, Germany) using DMSO-d6 as a solvent.  159 
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MTX-PGA (DMSO-d6; δ, ppm): 8.58 (s, 1H), 7.72-7.74 (m, 2H), 6.82-6.84 (d, 2H), 5.26-5.19 160 
(m, 2H), 4.95 (m, 1H), 4.79 (s, 2H), 4.37 (t, 1H), 4.23 (m, 2H), 4.18-3.88 (m, 6H), 3.63 (m, 2H), 161 
3.21 (s, 3H), 2.32 (m, 4H), 2.09 (m, 2H), 1.96 (m, 2H), 1.53 (m, 4H). 162 
PGA (DMSO-d6; δ, ppm): 5.26-5.19 (m, 2H), 4.95 (m, 1H), 4.27-4.24 (m, 2H), 4.18-3.88 (m, 163 
6H), 3.63 (m, 2H), 2.32 (m, 4H), 1.53 (m, 4H). 164 
2.3.3. Gel permeation chromatography (GPC) 165 
The molecular weights (number- and weight-average, Mn and Mw, respectively) were measured 166 
by gel permeation chromatography (PL50 Plus Polymer Laboratories system) equipped with a 167 
refractive index detector. Two mixed PL-Gel 5 µm bed (D) columns maintained at 50°C were 168 
used as a stationary phase using DMF containing 0.1% LiBr at a ﬂow rate of 1 mL/min as an 169 
eluent. Poly (methyl methacrylate) standards (Mn range of 1,810,000-505 g/mol) were employed 170 
to construct a calibration curve.  171 
2.3.4. UV analysis of MTX content 172 
The amount of conjugated MTX was analysed by UV/Vis spectrophotometer (UV-2600, 173 
Shimadzu Corporation, Kyoto, Japan). The absorbance value of the polymers was measured in 174 
DMF at a wavelength of 412 nm. The amount of conjugated MTX was calculated from a 175 
calibration curve of MTX over the range of 5-100 μg/mL. The molar absorptivity of MTX in 176 
DMF was 3.6643×103 M-1. 177 
2.4. Nanoparticle formation 178 
The nanoparticles of MTX-PGA polymers (MTX-PGA NPs) were prepared by a solvent 179 
diffusion and dialysis method [26]. In brief, 10 mg of the polymer was dissolved in 1 mL of 180 
DMSO. This solution was then added dropwise to 1 mL of aqueous phase while stirring to allow 181 
solvent diffusion. Then the colloidal dispersion was sealed in a dialysis tube (MWCO 1 kDa, 182 
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Spectra/Por® 6, Spectrum Laboratories, Inc., Dominguez, USA) for 24 h. The assembled 183 
nanoparticles were collected and kept as a dispersion until use.  184 
2.5. Analyses of particle size, size distribution and zeta potential 185 
The mean hydrodynamic diameter (z-ave), size distribution (PDI) and zeta potential (ZP) were 186 
assessed by Zetasizer NanoZS (Malvern Instrument Ltd., Malvern, UK). The sample without 187 
dilution was measured with He-Ne laser at a wavelength of 633 nm, an angle of 173° and 25°C. 188 
The ZP of nanoparticles was evaluated according to the electrophoretic mobility of the particles 189 
and calculated by the Helmholtz-Smoluchowsky equation. All measurements were performed in 190 
triplicate. 191 
2.6. Physical stability of nanoparticles in various pHs and ionic strengths 192 
To evaluate effects of pH and ionic strength of medium on the stability of the nanoparticles, the 193 
nanoparticles were diluted 10-fold in water adjusted to various pHs (1-13) using 5 M HCl or 194 
NaOH and to different ionic strengths (0.05-0.50 M sodium chloride solution; NaCl) using 5 M 195 
NaCl solution, respectively [31]. After mixing for 5 min, the sample was examined for 196 
hydrodynamic diameter, PDI and derived count rate. The derived count rate reflecting 197 
aggregation, sedimentation or dissociation of the nanoparticles is illustrated as kilo counts per 198 
second (kcps). The results are expressed as relative values of hydrodynamic diameter, PDI or 199 
kcps in the changed medium compared to an equal dilution of the nanoparticles in sterile water 200 
for injection. 201 
2.7. In vitro non-enzymatic and enzymatic drug release studies 202 
The drug release study of MTX-PGA NPs was performed in 25 mM phosphate buffered saline 203 
(PBS) pH 7.4 by dialysis method [26]. A typical protocol for release study was as follows. 204 
Freshly prepared MTX-PGA NPs (1 mL) were measured into a dialysis bag (MWCO 1000 Da, 205 
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Spectra/Por 6, Spectrum Laboratories, Inc., Dominguez, USA). The tightly sealed bag was 206 
immersed in the external medium (20 mL PBS pH 7.4 containing 0.02% w/v sodium azide). The 207 
release study was conducted at 37°C in the light-protected container with magnetic stirring at 208 
100 rpm. At predetermined times, sample (1 mL) was withdrawn from the external medium and 209 
was replenished with an equal volume of fresh PBS. In the case of enzymatic drug release study, 210 
porcine carboxylesterase (PCE) enzyme was mixed with the nanoparticle dispersion yielding 20 211 
and 50 units/mL of PCE [32-34]. The NPs mixture was filled into the dialysis bag and the release 212 
study was similarly performed as previously described. The enzymatic release study was 213 
conducted for 7 days. The MTX solution was employed as a control. The amount of MTX in the 214 
sample was analysed by HPLC (Shimadzu HPLC apparatus, Shimadzu Corporation, Kyoto, 215 
Japan) using Luna C18 column 150×4.6 mm plus a C18 guard column (Phenomenex, Torrance, 216 
USA) as a stationary phase and the mixture of 10% v/v acetonitrile and 90% v/v 0.05 M 217 
phosphate buffer pH 6.0 at a flow rate of 1.2 mL/min as a mobile phase.  218 
2.8. Cytotoxicity test in 791T osteosarcoma cells 219 
2.8.1. Cell culture experiment 220 
The osteosarcoma cell line 791T was grown as a monolayer in tissue culture polystyrene flasks 221 
in Eagles Minimum Essential Medium with the addition of 10% foetal bovine serum and 20 mM 222 
glutamine. Medium was changed every 2-3 days and cells were detached using 0.05% trypsin-223 
EDTA for subculture. The cells were kept in an incubator at 37°C with a humidified atmosphere 224 
with 5% CO2. 225 
2.8.2. Drug solution and nanoparticle suspension preparation 226 
Commercially available sterile MTX solution for injection (25 mg/mL, 55 mM in saline), and 227 
sterile-filtered nanoparticle suspensions (115-173 µM MTX equivalent) in PBS were diluted in 228 
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cell-culture medium to 9 half-log10-spaced concentrations spanning from (2 nM to 200 µM). 229 
MTX concentrations for the nanoparticle suspensions were calculated from UV absorption 230 
measurements. Drugs and nanoparticles were added as 2× solutions (100 µL/well) to build a 231 
dose-response from 1 nM to 100 µM. PBS concentration in all wells was kept at 10% v/v. For 232 
incubations longer than 72 h, media was refreshed with solutions/suspensions with the nominal 233 
MTX concentration equivalent. There were 6 technical replicates for each condition. 234 
2.8.3. Drug treatment in monolayer 235 
791T cells were seeded in flat bottom cell culture treated 96-well plates (100 µL, 236 
20×103 cells/mL) and left in the incubator for 24 h. Drug solution and nanoparticle suspensions 237 
were added from 2× stocks and left for 72 h. For the 6-day treatment experiments in monolayer, 238 
the old medium (150 µL) was removed, replaced with fresh drug solution (150 µL) and the cells 239 
cultured for another 72 h. On days 4 and 7 cell viability was determined using the resazurin 240 
assay. 241 
2.8.4. Drug treatment for spheroid cultures 242 
791T cells were seeded in round bottom ultra-low attachment 96-well plates (100 µL, 10×103 243 
cells/mL) and left to incubate for 72 h. MTX and MTX-PGA NPs were added on day 3 from 2× 244 
stock solutions, then refreshed on day 6. Spheroids were imaged on days 3, 6, and 9 and 245 
resazurin activity was determined on days 6 and 9. 246 
2.8.5. Resazurin assay 247 
Assay-ready resazurin solution (60 µM) was prepared from resazurin stock solution (440 µM in 248 
Hank’s Buffered Salt Solution) and fresh cell culture media. Spent medium (150 µL) was 249 
removed from each well and replaced with the same volume of assay resazurin solution. Cells in 250 
monolayer were incubated for 2 h, while spheroids were left for 4 h in the incubator. 251 
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Fluorescence was measured with an excitation wavelength of 530 nm and emission 590 nm on a 252 
Flexstation II plate reader. 253 
2.8.6. Spheroid imaging 254 
Brightfield spheroid images were acquired with a Nikon Ti Eclipse inverted microscope using 4 255 
× objective. Spheroid volume was determined with an in-house open source macro for the FiJi 256 
distribution of ImageJ [35, 36]. 257 
2.9. Cytotoxicity test in Saos-2 osteosarcoma cells 258 
2.9.1. Cell culture experiment 259 
Saos-2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 260 
10% FBS and penicillin/streptomycin (100 units/mL) in a 5% CO2 humidified incubator at 37°C. 261 
The medium was change every 2-3 days. For subculture, the cells were trypsinised using 0.25% 262 
trypsin-EDTA. 263 
2.9.2. Drug solution and nanoparticle suspension preparation 264 
MTX stock solution was prepared in Dulbecco’s PBS pH 7.4. The stock solutions of MTX and 265 
nanoparticles were filtered through sterile 0.22 µm syringe filter and subsequently diluted in 266 
DMEM to the concentration range of 0.002 – 220 µM.  267 
2.9.3. Drug treatment in Saos-2 monolayer 268 
Saos-2 cells (100 µL) were seeded in 96-well plate at a cell density of 2,000 cells/well and 269 
incubated under 5% CO2 humidified atmosphere at 37°C for 24 h. After aspirating the medium, 270 
100 µL of sample was subsequently added into each well and the cells were incubated for 72 h. 271 
After that PrestoBlue® cell viability reagent (10 µL) was added in each well and then incubated 272 
for 50 min in the incubator. The absorbance was measured at 570 and 600 nm as measuring and 273 
reference wavelengths, respectively, by a microplate reader (Tecan’s Infinite® 200 NanoQuant, 274 
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Männedorf, Switzerland). The measurement was performed in six replicates for at least 2 275 
different days.  276 
2.10. Statistical analysis 277 
The z-ave, PDI and ZP of MTX-PGA NPs were statistically compared using one-way ANOVA 278 
(IBM SPSS statistic 21). The significant difference is considered when p-value is less than 0.05.  279 
Data from resazurin experiments were normalized to untreated controls (100% viability) and 280 
cell-free wells (0% viability). The volume of untreated spheroids was taken as 100% viability 281 
and 0 as 0% viability. Four-parameter logistic dose-response curves were fitted to the resazurin, 282 
volume and  PrestoBlue® data in GraphPad Prism, the top was constrained to 100 and the bottom 283 
to ≥0. IC50s used are the inflection point of the dose-response curve, half-way between the 284 
untreated controls (100%) and the curve bottom (maximum effect). Results are displayed as 285 
mean ± SD unless stated otherwise. 286 
3. Results and Discussion 287 
3.1. Conjugation of MTX onto PGA backbone 288 
By a simple coupling reaction, various amounts of MTX were successfully conjugated to the 289 
PGA backbone, which were designated X%MTX-PGA, with X corresponding to the nominal 290 
mole% MTX per polymer repeating unit. As compared to the IR-ATR spectrum of PGA (Fig. 291 
1A), the sharp C=O stretching peak at 1718 cm-1 corresponding to the ester coupling of MTX 292 
and glycerol adipate repeating unit overlapped to that ester along the PGA backbone. Other 293 
characteristics of MTX were also observed in the spectra. The peaks of N-H bending of amine, 294 
C=O stretching of amide bond, C=C stretching of aromatic ring of MTX were overlapping to 295 
each other at 1624, 1600 and 1553 cm-1, respectively. However, the intensity of these peaks 296 
increased with the MTX content. The peaks of N-H stretching of amine and amide occurred over 297 
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the region of 2950-2800 cm-1 which overlapped with O-H stretching of PGA. As previously 298 
reported on the NMR spectrum of PGA, the adipic protons presented at 1.5 and 2.3 ppm in 299 
DMSO-d6 (Fig. 1B) which slightly shifted to upfield region as compared to those in acetone-d6 300 
[29]. Meanwhile, the protons related to glycerol repeating units were apparent in the region of 301 
3.6 ppm and 4.9 ppm. The methine protons corresponding to 1,2 and 1,3 di-substituted 302 
glycerides occurred at 5.20 ppm coinciding with the presence of the methine proton of 1,2,3 tri-303 
substituted glycerol units at 5.26 ppm. The latter proton indicates the tri-substituted repetitive 304 
glycerol unit of PGA polymer. The conjugation of MTX at free hydroxyl group available on 305 
glycerol units resulted in the shift of methylene proton peaks from 3.6 ppm to 4.2 ppm. The 306 
methine proton at 5.26 ppm increased when higher amounts of MTX were conjugated, 307 
confirming the functionalization of the secondary hydroxyl group. The glycerol and adipic 308 
protons of MTX-PGA polymers were still observed at a similar chemical shift to those of PGA. 309 
In addition, the characteristic protons of MTX were also observed in the NMR spectra.  310 
Fig. 1 311 
The percent MTX conjugation can be calculated from NMR spectra based on the pteridine 312 
proton of MTX at 8.58 ppm and the methylene protons in adipate units of PGA at 2.32 ppm as 313 
shown in the equation (1). The methine proton at 5.26 ppm could not be accounted for in the 314 
calculation of %conjugated MTX due to the interference of methine proton of di-substituted 315 
repeating units. The results are illustrated in Table 1. The % conjugated MTX was found to be 316 
7.0, 14.5 and 27.5% with respect to number of repeating units of PGA chain for 10%, 20% and 317 
30%MTX-PGA, respectively. Using these NMR data, the conjugation efficiency based on 318 
theoretical conjugation reached 58.3, 60.4 and 76.4% for 10%, 20% and 30%MTX-PGA, 319 
respectively. The amount of conjugated MTX was further confirmed by UV spectrophotometry. 320 
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The analysed amount of MTX was found to be 8.86±0.32, 17.33±1.25, 33.26±4.72 %mole MTX 321 
conjugated per mole of polymer repeating unit. The difference between the analysis using NMR 322 
and UV spectrophotometry is probably due to changes in extinction coefficients on conjugation 323 
of MTX. 324 
𝐼𝐼8.58 𝑝𝑝𝑝𝑝𝑝𝑝 1⁄
𝐼𝐼2.32 𝑝𝑝𝑝𝑝𝑝𝑝 4⁄ × 100         (1) 325 
where I8.58 ppm and I2.32 ppm are the integrals of pteridine proton of MTX at 8.58 ppm and 326 
methylene protons in adipate repeating units of PGA at 2.32 ppm, respectively. 327 
Table 1 328 
The Mn of PGA starting materials was 13000 g/mol. After conjugation, the Mn of MTX-PGA 329 
polymers increased gradually with %MTX conjugation. The Mw/Mn values of all MTX-PGA 330 
polymers decreased compared to that of PGA due to the purification of polymer by precipitation 331 
in which the unconjugated PGA could be removed during washing which may tend to selectively 332 
remove the lower molecular weight polymers. These results indicated that MTX was 333 
successfully conjugated along PGA backbone by a simple carbodiimide-mediated coupling 334 
reaction.  335 
3.2. Nanoparticle formation 336 
The MTX-PGA NPs were prepared in deionized water by solvent diffusion-dialysis method. As 337 
shown in Fig. 2, the hydrodynamic diameter of MTX-PGA NPs tended to increase with %MTX 338 
except for 20%MTX-PGA nanoparticles whose value was extraordinarily larger than the others. 339 
The particle size of 20% and 30%MTX-PGA was approximately 6 and 2 times larger than 340 
10%MTX-PGA NPs, respectively. The increasing particle size with drug loading may be due to 341 
higher steric hindrance and bulkiness inside the nanoparticle core as a result of poor packing of 342 
drug moiety as seen in the case of 20%MTX-PGA NPs. Meanwhile, for 30%MTX, a better 343 
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compaction of the nanoparticles was achieved, probably due to increased hydrophobicity of the 344 
polymer-drug conjugates. The size distribution of 10% and 30%MTX-PGA NPs was narrow 345 
while, that of 20%MTX-PGA NPs was quite broad. The size distribution related to the diameter 346 
of the nanoparticles. A greater negative surface charge of nanoparticles was observed when 347 
increasing %MTX in particular to 30%MTX-PGA NPs indicating that an increasing number of 348 
MTX moieties was displayed on the nanoparticle surface. Combining the results of 349 
hydrodynamic diameter and zeta potential, the dramatic size increase of 20%MTX-PGA NPs 350 
was thought to result from destabilization of the nanoparticles followed by agglomeration upon 351 
particle formation. 352 
Fig. 2 353 
From these results, we anticipated that the pH of preparation medium may affect the particle 354 
formation due to a presence of pH-sensitive moiety in the drug molecule. Therefore, the effect of 355 
pH of preparation medium was further investigated. Two pH media were used, namely acidic pH 356 
3.0 medium and pH 7.4 medium. As expected, the pH of preparation medium considerably 357 
affected the hydrodynamic diameter. In medium pH 7.4, the particle size decreased with 358 
increasing %MTX. Meanwhile, the diameter of nanoparticles gradually increased in acidic pH 359 
3.0 medium with increasing %MTX. This result was likely caused by the acid dissociation of 360 
MTX in different medium pHs. MTX possesses three pKa value ranges of 3.3-3.4, 3.9-4.7 and 361 
5.3-5.7 at alpha and gamma carboxyl groups and pteridine ring, respectively [37, 38]. The 362 
gamma carboxyl of MTX is more reactive so tend to conjugate to hydroxyl pendant of PGA 363 
more readily resulting in a higher preponderance of free alpha carboxyl group [39], so the free 364 
carboxyl and pteridine of MTX are involved in the dissociation of MTX in the medium. MTX 365 
protons were almost totally dissociated in medium pH 7.4 [40] while acid groups remained 366 
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unionized at pH 3.0. The ionized MTX molecule exhibited more hydrophilicity and favoured an 367 
aqueous phase. Thus the drug molecules were preferably presented on the surface of particles 368 
and fewer molecules incorporated in the core thus dramatically reducing the particle size to less 369 
than 100 nm. On the other hand, the acidic aqueous phase suppressed the dissociation of 370 
carboxylic group of MTX which enhanced the hydrophobicity of drug molecules and 371 
nanoparticle core. Thus, it enlarged the MTX-PGA NPs with increasing MTX content. The size 372 
distribution of the nanoparticles increased in acidic medium but declined in pH 7.4 medium 373 
relative to that in deionized water. The zeta potential of MTX-PGA NPs became positive and 374 
more negative in media pH 3.0 and 7.4, respectively. The difference in amount of MTX did not 375 
affect the zeta potential (p-value>0.05). The change of surface charge of MTX-PGA NPs was 376 
possibly as a result of ionised hydronium and hydroxyl species in the acidic and pH 7.4 media, 377 
respectively. 378 
3.3. Physical stability of nanoparticles in various pHs and ionic strengths 379 
The physical stability of MTX-PGA NP dispersion was evaluated in various pHs and ionic 380 
strengths. The relative hydrodynamic diameter, PDI and kcps compared to the nanoparticles 381 
equally diluted in sterile water for injection are summarised in Fig. 3. Regarding the effect of pH, 382 
the hydrodynamic diameter of all MTX-PGA NPs increased by at least twice in extremely low 383 
and high pHs (1-3 and 11-13). The size distribution was also broadened particularly to 384 
10%MTX-PGA NPs over pH range of 1-3 and 11-13. The relative kcps of MTX-PGA NPs in pH 385 
1-3 considerably increased especially 20%MTX-PGA NPs whilst it decreased in pH 11-13. 386 
Principally, an increase of count rate suggests an occurrence of aggregation of particles whereas 387 
a decrease of count rate indicates the sedimentation or dissociation of nanoparticles [41, 42]. 388 
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Combining the hydrodynamic diameter and kcps data, the MTX-PGA NPs aggregated into large 389 
particles in media with pH of less than 5 and dissociated or settled down in media pH over 7.  390 
Fig. 3 391 
Regarding the effect of ionic strength, the nanoparticles started to aggregate in 0.25 M NaCl as 392 
seen by dramatic increases of hydrodynamic diameter and PDI. Meanwhile, the increment of 393 
kcps was initially observed in 0.15 M NaCl particular to 20%MTX-PGA NPs whereas the others 394 
remained almost unchanged. The results indicated that all MTX-PGA NPs aggregated in the 395 
medium with NaCl concentration of 0.25 M or higher. 10%MTX-PGA NPs and 30%MTX-PGA 396 
NPs were physically stable in the medium with 0.15 M NaCl or lower. From the results above, it 397 
was suggested that the MTX-PGA NPs were physically stable in physiological relevant medium 398 
with pH range of 5-9 and ionic strength of lower than 0.15 M NaCl.  399 
3.4. In vitro drug release experiment 400 
We have chosen carboxylesterase (PCE) as an example of an enzyme which can degrade PGA to 401 
investigate drug release. The hydrolytic release of MTX from MTX-PGA NPs was investigated 402 
in PBS pH 7.4 over 30 days. The results are graphically demonstrated in Fig. 4. The control 403 
MTX solution showed a rapid diffusion from the dialysis tubing with over 90% release within 8 404 
h. Meanwhile, the MTX release from all MTX-PGA NPs was considerably slower over 30 days 405 
showing effective conjugation of the drug to the polymer with only a slow hydrolytic 406 
degradation. The maximum MTX release provided by 30%MTX-PGA NPs reached only 17% at 407 
day 30. Regarding various %MTX conjugations, the extent of MTX release depended on the 408 
amount of conjugated MTX. 10%MTX-PGA NPs released the lowest amount of MTX by only 409 
9% at the end of experiment even though they had smallest average diameter after preparation. 410 
The presence of esterase enzyme in PBS accelerated the release of MTX from 30%MTX-PGA 411 
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NPs. Moreover, the rate of MTX release escalated with the PCE concentration. At day 7, 40% 412 
and 62% of MTX were released in PBS containing 20 and 50 units/mL PCE, respectively. The 413 
liberated MTX peak in HPLC chromatogram was identical to the MTX standard peak (data not 414 
shown) suggesting that the degradation of MTX-PGA NPs could be catalysed by esterase 415 
enzyme liberating intact MTX molecules whose pharmacological activity should not be changed. 416 
There are a wide range of proteolytic enzymes present in the lysosomal environment with 417 
different specificities and this can be illustrated with a previous paper by our group which 418 
reported the uptake and metabolism of PGA nanoparticles in DAOY cells [43]. The PGA 419 
nanoparticles are taken up by the cells which then enter endosomes and lysosomes and undergo 420 
fast degradation in the cells.  This environment is likely to result in a much faster and complete 421 
degradation and drug release than seen in the present experiment. However the above experiment 422 
demonstrates the potential for an enzymic release of free drug from this polymer which is more 423 
effective than the release of MTX previously reported from HSA-MTX conjugates using 424 
lysosomal enzyme preparations [19, 20]. 425 
Fig. 4 426 
3.5. Cell response experiment 427 
To further confirm the potency of MTX-PGA NPs, a cell response experiment was performed in 428 
osteosarcoma 791T cells. 10%MTX-PGA NPs and 30%MTX-PGA NPs were selected to study 429 
their cell response in comparison with the clinically available MTX solution. MTX and MTX-430 
PGA NPs elicited a dose dependent decrease in 791T cell viability after incubation for 72 h (Fig. 431 
5). The cytotoxic effects of MTX and the nanoparticles were more pronounced in monolayer 432 
cultures (Fig. 5A), where MTX had an IC50 of 15 nM and killed 75% of cells. These results are 433 
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in agreement with previous studies on the cytotoxic effects of MTX in monolayer by Garnett et 434 
al [4]. 435 
Fig. 5 436 
Present results of MTX-PGA NPs and historic results with HSA-MTX by Garnett et al. (Fig. S1 437 
in supplementary data) are compared using 791T cells in 2D cell culture. Values in parenthesis 438 
give % drug loading w/w as drug loading appears to affect cytotoxicity. The MTX-PGA 439 
analogues were 2.6 and 11.3 times less potent compared to free MTX. This is significantly better 440 
compared to the >300× potency differences seen with the HSA-MTX conjugates (Table 2). The 441 
increased potency of the MTX-PGA analogues compared to HSA-MTX is probably due to the 442 
quick degradation of PGA in the lysosomes once internalized in the cells. MTX-PGA NPs were 443 
probably degraded to free drug by enzyme-catalysed hydrolysis as seen in the enzymatic release 444 
experiment. This is in contrast to HSA-MTX conjugates which mainly released the lysyl-MTX 445 
derivatives [19, 20]. It has been reported that the efficiency of dihydrofolate reductase inhibition 446 
of MTX is lowered by conjugation due to steric interference between the enzyme and the 447 
modified drug [44, 45]. Therefore, the higher potency of MTX-PGA NPs as compared to HSA-448 
MTX may be attributed to improved free drug release. 449 
Table 2 450 
It has been demonstrated in previous publications by our group that there is a greater uptake of 451 
PGA nanoparticles into DAOY tumour spheroids than for similar mixed rat neonatal normal 452 
brain cells [46], and we have recently published a convenient method for determination of 453 
cytotoxicity in spheroid cultures [35]. We have therefore also investigated the cytotoxicity of 454 
MTX-PGA NPs in 791T spheroids compared to free drug. The results for resazurin reduction in 455 
791T spheroids were considerably more variable compared to monolayers resulting in 456 
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ambiguous curve-fits (Fig. 5B). Nevertheless, a similar trend was observed, where free MTX 457 
was the most potent, closely followed by 30%MTX-PGA (1.2 times IC50 difference) and 458 
10%MTX-PGA was the least potent (30 times IC50 difference). When spheroid volume was used 459 
to estimate spheroid viability, variability was much lower, curve fitting and the estimation of 460 
IC50s and maximal effects improved (Fig. 5C). Although MTX was still active in the nanomolar 461 
range (IC50=45 nM), cell viability remained above 50% even at micromolar concentrations. 462 
Increased resistance to chemotherapy when cells are cultured in 3D has been reported before [35, 463 
47, 48]. Notwithstanding the decrease in sensitivity, the potency differences between MTX and 464 
the MTX-PGA conjugates remained unchanged (Fig. 5D).  Longer incubation periods (6 days) 465 
produced even more potent responses to MTX with lower IC50s and smaller surviving fraction of 466 
cells, along with similar potency ratio between the free drug and the conjugates (Fig. S2 in 467 
supplementary data).  It was disappointing that the 3D culture conditions did not show an 468 
improvement in relative activity of MTX-PGA/MTX compared to 2D culture but this may be 469 
due to other factors like the physicochemical properties of the nanoparticles and their cellular 470 
interactions. 471 
Further investigation was performed in another osteosarcoma cell line, Saos-2, to further confirm 472 
whether the MTX-PGA NPs would affect in a similar or different fashion as observed in 791T 473 
cells. The IC50 values of MTX-PGA NPs against Saos-2 cells are summarised in Table 2. MTX 474 
had an IC50 of 210.9 µM in Saos-2 and only resulted in 47.7% cell viability even at the highest 475 
concentration of MTX tested in this study. This value was high in the micromolar range and 476 
extremely high compared to the value in 791T cells but was consistent with previous studies on 477 
low MTX-responsive or MTX-resistant Saos-2 cells [49, 50]. In the case of MTX-PGA NPs, 478 
10%MTX-PGA NPs and 30%MTX-PGA NPs were relatively unresponsive on Saos-2 in 479 
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comparison to 791T cells with IC50s of 26.8 and 20.2 µM, respectively. Although the IC50 values 480 
of the nanoparticles on Saos-2 cells were still in the micromolar range, they possessed 7.9 and 481 
10.4 times higher potency than free drug, respectively. This result revealed that the MTX-PGA 482 
NPs provided better relative potency in Saos-2 cells than 791T cells suggesting the improved 483 
efficacy of MTX-PGA conjugates in Saos-2 cells. As evidenced by the previous reports [49, 50], 484 
the low MTX-responsive or MTX-resistant Saos-2 cells are attributed to a reduction of MTX 485 
uptake by RFC, an overexpression of DHFR protein, an increment of MTX efflux due to 486 
overexpression of multidrug resistant protein, a reduction of MTX polyglutamylation, a decrease 487 
of DHFR affinity to MTX and the combination of these mechanisms [50-52]. The improved 488 
efficacy in Saos-2 cells by the MTX-PGA NPs may be attributed to overcoming one of the 489 
resistance mechanisms. Further work will be needed to investigate the mechanistic resistance of 490 
Saos-2 to MTX and to evaluate whether the MTX-PGA NPs can be used in MTX-resistant 491 
osteosarcoma. 492 
5. Conclusion 493 
Our study showed the feasibility of the conjugation of anticancer drug, MTX, to a PGA 494 
backbone, the first polymer-anticancer drug conjugate reported with this polymer. The MTX-495 
PGA conjugates contained high molar MTX content by 27.5 mole% and showed promising 496 
characteristics in terms of particle properties, physical stability in the physiological medium, 497 
stability of polymer-drug conjugate linker over 30 days and enzymatic degradability. Although 498 
the MTX-PGA NPs showed lower cytotoxicity to 791T cells than free MTX, 30%MTX-PGA 499 
NPs were only slightly less potent than MTX in either 2D or 3D cultures. Nonetheless, the 500 
nanoparticles exhibited relatively higher toxicity to Saos-2 cells than the parent drug. The 501 
improved efficacy of MTX in Saos-2 cells rather than 791T cells was possibly due to 502 
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surmounting MTX-resistant mechanism in this cell. However, further work is needed to 503 
determine the mechanism overcoming the drug resistance by MTX-PGA NPs. Taking the 504 
enzymic degradation results together with the cytotoxicity data and previous reports on the 505 
degradation of PGA in the lysosomal compartment of cells, this strongly suggests that this PGA 506 
polymer conjugate does not require a complex linker between drug and polymer. This opens the 507 
way to a possible new paradigm for polymer-drug conjugates which have a simpler synthesis 508 
together with a more effective mechanism of action. Nevertheless, further improvement of 509 
potency and greater specificity of the conjugate may be needed for this type of polymer-drug 510 
conjugate and we are continuing to investigate these possible improvements.   511 
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Figure and table captions 616 
Figure 1. IR-ATR spectra (A) and 1H NMR spectra (B) of PGA, MTX and MTX-PGA 617 
conjugates. 618 
Figure 2. Mean hydrodynamic diameter (z-ave, A), size distribution (PDI, B) and zeta potential 619 
(ZP, C) of MTX-PGA NPs at various %MTX conjugations. An error bar indicates the standard 620 
deviation from three measurements. *Statistically significant difference comparing different 621 
amount of conjugated MTX (p-value<0.05). **Statistically significant difference compared to 622 
MTX-PGA NPs prepared in DI water at an equal amount of conjugated MTX (p-value<0.05). 623 
Figure 3. Relative hydrodynamic diameter (A and D), PDI (B and E) and kcps (C and F) of 624 
MTX-PGA NPs in various pHs (left column) and ionic strengths (right column) of media as 625 
compared to those in an equal dilution in sterile water for injection. Error bar indicates standard 626 
deviation of three measurements. *Statistically significant difference when comparing the same 627 
formulation in different media (p-value<0.05). **Insignificant difference when comparing the 628 
same formulation in different media (p-value>0.05). 629 
Figure 4. Release profiles of MTX from MTX-PGA NPs in PBS pH 7.4 with an absence of 630 
enzyme for 30 days and the presence of 20 and 50 units/mL PCE at 37°C for 7 days. Error bars 631 
indicate standard deviation from three experiments.  632 
Figure 5. Viability of 791T monolayers and spheroids treated with MTX and MTX-PGA NPs 633 
for 3 days. A-resazurin viability assay for 791T cells treated in monolayer, B-resazurin viability 634 
assay for 791T spheroids, C-dose-response curves for spheroid volume. D-table summarising the 635 
IC50 and maximum effect with the corresponding 95% confidence intervals for the estimates. 636 
MTX (black circles), 10%MTX-PGA NPs (red triangles) or 30%MTX-PGA (blue diamonds) 637 
Table 1 Molecular characteristics of PGA and MTX-PGA polymers 638 
29 
Table 2 Comparison of relative efficacy of polymer-drug conjugates (PDC) with MTX 639 
